PHC320H1 Lecture : Iressa
Document Summary
The egf receptor: rtk family of cell surface receptors, receptors of egfr subgroup essential for embryonic development and adult tissue. Includes epidermal growth factor receptor (egfr/erb1/her1) and its relatives homeostasis in vertebrates and invertebrates. Abnormal activation associated with a variety of cancers. Prognostic significance of egfr overexpression in selected cancers: poor prognosis, low survival, high risk of metastases. Treat advanced nsclc with prior chemotherapy prescription. Not a great response rate: gefitinib + chemo, gefinitib, no difference in survival or time to progression, isel trial. No difference, but subgroup analysis shoed survival benfit in never- smokers and asians significant difference: only a small proportion of patients with nsclc shows dramatic responses to. Iressa: factors that favor gefitinib sensitivity, woman, non-smoker, japanese, adenocarcinoma. Charactersistcs of patients with nsclc that respond to gefitinib: egfr mutation. H3255 line has l858r mutation which is very sensitive to gefinitib compared to wild types. Gefinitib sensitizing egfr mutations in lung cancer activates anti-apoptotic pathways.